BioStock: Coegin Pharma takes advantage of decentralised clinical trials

Traditional clinical trials can be lengthy and are often a burden for patients involved. Patient recruitment is a major contributor to study delays and, thus, dragged-out drug development timelines. In response, we are seeing the rise of decentralised clinical trials (DCTs) – clinical trials that offer effective digital patient recruitment through digitalisation and a smooth journey for the patients throughout the study period. Coegin Pharma is a prime example of a pharma company taking advantage of DCTs through its collaboration with Studies&Me, an innovative virtual contract research organisation (CRO) based in Denmark. BioStock takes a closer look.

Read the full interview with CEO of Studie&Me, John Zibert and CEO of Coegin Pharma, Tore Duvold at biostock.se:

https://www.biostock.se/en/coegin-pharma-takes-advantage-of-decentralised-clinical-trials/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/